251 related articles for article (PubMed ID: 15642673)
21. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
22. Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours.
Nieboer P; de Vries EG; Mulder NH; Sleijfer DT; Willemse PH; Hospers GA; Gietema JA; Sluiter WJ; van Der Graaf WT
Bone Marrow Transplant; 2001 May; 27(9):959-66. PubMed ID: 11436106
[TBL] [Abstract][Full Text] [Related]
23. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
24. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
25. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
Wildes TM; Augustin KM; Sempek D; Zhang QJ; Vij R; Dipersio JF; Devine SM
Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205
[TBL] [Abstract][Full Text] [Related]
26. Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma.
Rossi A; Cortelazzo S; Bellavita P; Viero P; Bassan R; Comotti B; Marchioli R; Marfisi RM; Rambaldi A; Barbui T
Br J Haematol; 1997 Mar; 96(3):620-6. PubMed ID: 9054673
[TBL] [Abstract][Full Text] [Related]
27. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy with autologous marrow rescue for malignant brain tumors: analysis of the impact of prior chemotherapy and cranio-spinal irradiation on hematopoietic recovery.
Faulkner LB; Lindsley KL; Kher U; Heller G; Black P; Finlay JL
Bone Marrow Transplant; 1996 Mar; 17(3):389-94. PubMed ID: 8704692
[TBL] [Abstract][Full Text] [Related]
29. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
30. Quantity and origin of transplanted autologous blood cells are independent factors associated with speed of postransplant hematological reconstitution.
Rogulj D; Batinić D; Nemet D; Petrovecki M
Croat Med J; 1999 Sep; 40(3):404-8. PubMed ID: 10411969
[TBL] [Abstract][Full Text] [Related]
31. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
Kasow KA; Sims-Poston L; Eldridge P; Hale GA
Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
[TBL] [Abstract][Full Text] [Related]
32. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
Vicent MG; Madero L; Chamorro L; Madero R; Diaz MA
Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
34. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Phillips GL; Abboud CN; Bernstein SH; Friedberg JW; Ifthikharuddin JJ; Lancet JE; Liesveld JL; Spreng E; Johnson V; Chapman M; Vesole DH
Semin Oncol; 2004 Dec; 31(6 Suppl 18):59-61. PubMed ID: 15726525
[TBL] [Abstract][Full Text] [Related]
35. Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma.
Barbui T; Cortelazzo S; Rossi A; Viero P; Bellavita P; Buelli M; Fracassetti D; Bassan R; Comotti B; Marchioli R; Marfisi RM; Rambaldi A
Cancer Chemother Pharmacol; 1996; 38 Suppl():S110-4. PubMed ID: 8765429
[TBL] [Abstract][Full Text] [Related]
36. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers.
Goterris R; Hernández-Boluda JC; Teruel A; Gómez C; Lis MJ; Terol MJ; Tormo M; Solano C; Arbona C
Bone Marrow Transplant; 2005 Nov; 36(10):847-53. PubMed ID: 16113660
[TBL] [Abstract][Full Text] [Related]
37. Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC).
Bredeson C; Malcolm J; Davis M; Bence-Bruckler I; Kearns B; Huebsch L
Bone Marrow Transplant; 1997 Nov; 20(10):889-96. PubMed ID: 9404932
[TBL] [Abstract][Full Text] [Related]
38. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP.
Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Kim SW; Jang S; Park CJ; Chi HS; Huh J; Suh C
Transfusion; 2007 Aug; 47(8):1447-54. PubMed ID: 17655589
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
Dean R; Masci P; Pohlman B; Andresen S; Serafino S; Sobecks R; Kuczkowski E; Curtis J; Maciejewski J; Rybicki L; Kalaycio M; Hsi E; Theil K; Bolwell BJ
Bone Marrow Transplant; 2005 Dec; 36(12):1049-52. PubMed ID: 16247431
[TBL] [Abstract][Full Text] [Related]
40. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]